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Abstract Hypoglycemia is the most frequent complica-
tion of insulin therapy in patients with type 1 diabetes.
Since the brain is reliant on circulating glucose as its main
source of energy, hypoglycemia poses a threat for normal
brain function. Paradoxically, although hypoglycemia
commonly induces immediate decline in cognitive func-
tion, long-lasting changes in brain structure and cognitive
function are uncommon in patients with type 1 diabetes. In
fact, recurrent hypoglycemia initiates a process of habitu-
ation that suppresses hormonal responses to and impairs
awareness of subsequent hypoglycemia, which has been
attributed to adaptations in the brain. These observations
sparked great scientific interest into the brain’s handling of
glucose during (recurrent) hypoglycemia. Various neu-
roimaging techniques have been employed to study brain
(glucose) metabolism, including PET, fMRI, MRS and
ASL. This review discusses what is currently known about
cerebral metabolism during hypoglycemia, and how find-
ings obtained by functional and metabolic neuroimaging
techniques contributed to this knowledge.
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Abbreviations
ASL Arterial spin labeling
ANLS Astrocyte-neuron lactate shuttle
BOLD Blood oxygenation level dependent
CBF Cerebral blood flow
CMRglc Cerebral metabolic rate of glucose
CMRO2 Cerebral oxygen metabolic rate
ECF Extracellular fluid
FDG 18F-Fluoro-2-deoxy-D-glucose
fMRI Functional magnetic resonance imaging
GABA Gamma-aminobutyric acid
Glc-6-P Glucose-6-phosphate
GLUT Glucose transporter protein
GPR81 G-protein-coupled receptor 81
HAAF Hypoglycemia-associated autonomic failure
HbA1c Glycosylated hemoglobin
MCA Monocarboxylic acid
MCTs Monocarboxylic acid transporters
MRS Magnetic resonance spectroscopy
NALS Neuron-astrocyte lactate shuttle
PET Positron emission tomography
RF Radiofrequency







The brain is one of the most metabolically active organs in
the body and it consumes energy disproportionate to its
size. In humans, the brain represents only about 2 % of
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total body weight, yet it accounts for approximately 20 %
of the body’s oxygen use and 25 % of the body’s use of
glucose. Glucose is the primary fuel for the adult brain. In
young adults, the ‘resting’ brain consumes approximately
110 g of glucose per day, i.e. 5.5 mg glucose per 100 g of
brain tissue per minute [1]. Since the brain’s energy stores
are small, normal brain function depends on a continuous
supply of glucose from the bloodstream. Under normal
conditions, the human body takes great effort and is very
efficient in avoiding hypoglycemia in almost all circum-
stances to maintain sufficient glucose delivery to the brain.
Type 1 diabetes mellitus is an autoimmune-mediated
disease, characterized by destruction of most, if not all, of
the insulin-producing capacity of pancreatic beta-cells. As
a consequence, supplemental insulin treatment is required
to maintain glucose control and decrease the risk of com-
plications resulting from hyperglycemia [2]. Unfortunately,
therapeutic insulin is still poor at mimicking the pharma-
cology of endogenous insulin. As a consequence, people
with type 1 diabetes—in particular those aiming for strict
glycemic control—are at continuous risk of hypoglycemia,
the average frequency of which has been estimated at two
non-severe, symptomatic episodes per week [3–5] and one
severe, potentially hazardous event, per year [4, 6, 7].
Although there is substantial variation in both the rate and
the severity of hypoglycemia, both between and within
persons [4, 8], this estimation means that the brains of
people with type 1 diabetes are exposed to many thousands
of hypoglycemic episodes over a lifetime of diabetes.
Studying brain metabolism during hypoglycemia may
reveal the potential harmful effects of (recurrent) hypo-
glycemia on the brain and may increase our understanding
of metabolic adaptations that might underlie impairments
in the defenses against hypoglycemia [9]. Modern neu-
roimaging techniques have enabled the study of cerebral
metabolism in vivo in a relatively non-invasive manner.
This review will focus on the effect of hypoglycemia on
brain (glucose) metabolism, with a particular emphasis on
recent findings from functional and metabolic neuroimag-
ing studies. Basic mechanisms of brain energy metabolism
and neuroimaging techniques will be discussed briefly.
Glucose counterregulation
In healthy, non-diabetic humans, hypoglycemia is unlikely
to ever occur due to a hierarchically coordinated system
that integrates insulin secretion and counterregulatory
hormone and symptom responses [10, 11]. When glucose
levels in the low-physiological range (e.g. late post-ab-
sorptive or fasting state) tend to fall, insulin secretion is
suppressed to such an extent that true hypoglycemia can
almost always be prevented. When insulin is given to
experimentally induce hypoglycemia in people without
diabetes, glucose levels at or below *3.8 mmol/L will
induce a glucagon response, the secretion of which by
pancreatic alpha-cells is probably controlled by the
neighboring beta-cells [10, 11]. Such a glucose level also
stimulates the secretion of adrenaline, whereas slightly
lower levels are needed to elicit autonomic warning
symptoms, such as sweating, palpitations, trembling and
feeling hungry [10, 11]. These symptoms are aimed at
initiating a behavioral response (i.e. ingesting carbohy-
drates). Further falls in plasma glucose values result in
neuroglycopenic symptoms, which range from mild cog-
nitive impairment, such as difficulty in concentrating, to
overt confusion and even coma or seizures in its most
severe form [10, 11].
In patients with type 1 diabetes, hypoglycemia typically
results from the interplay between therapeutic peripheral
hyperinsulinemia and impaired defenses against falling
plasma glucose levels [10]. These impairments first include
the inability to decrease insulin and to increase glucagon in
response to hypoglycemia. The latter is not a structural
defect, but specific for hypoglycemia and probably sec-
ondary to loss of control by non-functioning beta-cells
[12]. In patients with longer diabetes duration and more
frequent exposure to hypoglycemia, adrenaline responses
to hypoglycemia become attenuated, in part due to a shift
of these responses to lower glucose values [13]. The
defective adrenaline responses are associated with,
although not necessarily the cause of, similar defects in the
emergence of autonomic symptom responses [14, 15].
Disappearance of these symptoms interferes with the
ability to timely and accurately perceive, interpret and
respond to falling plasma glucose levels. This inability is
known as the clinical syndrome of impaired awareness of
hypoglycemia and increases the risk of particularly severe
hypoglycemia, defined as those events requiring assistance
from another person [16], by a factor of six or more [17,
18]. Both the attenuated adrenaline response and impaired
awareness of hypoglycemia are usually the result of (re-
current) antecedent hypoglycemia rather than of autonomic
neuropathy, for which the term ‘hypoglycemia-associated
autonomic failure’ (HAAF) has been introduced [19].
HAAF can be effectively treated by several weeks to
months of scrupulous avoidance of hypoglycemia [15, 20,
21], although it appears that the symptomatic component
responds earlier and better than the hormonal component
[15]. The underlying mechanism(s) explaining the attenu-
ating effect of prior hypoglycemia on responses to
subsequent events have not been fully elucidated. How-
ever, there is agreement that alterations in the brain play a
pivotal role.
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Morbidity associated with hypoglycemia
The glucose level at which cognitive function declines is
subject to substantial variation; in some people cognitive
dysfunction already occurs at plasma glucose levels
between 3.0 and 4.0 mmol/L, whereas others continue to
function well at levels below 2.5 mmol/L [8, 22]. Almost
all domains of cognitive function are potentially at risk
during acute hypoglycemia, with complex tasks (e.g. car
driving) being affected earlier than simple tasks [23, 24].
Prolonged and/or profoundly severe hypoglycemia may
eventually cause neuronal death [25, 26]. The cerebral
cortex and hippocampus are the most vulnerable regions in
the brain to be injured by severe hypoglycemia, while the
brain stem and cerebellum are most resistant [27]. How-
ever, although persistent vegetative states or brain death
resulting from hypoglycemia have been described [28–30],
most patients with type 1 diabetes recover uneventfully
from even severe hypoglycemia complicated by seizures or
coma, especially when they are young and in good clinical
condition. In addition, evidence for an association between
multiple episodes of severe hypoglycemia and long-term
cognitive decline in people with type 1 diabetes is lacking
[31, 32]. Finally, although 4–10 % of all deaths in patients
with type 1 diabetes have been attributed to hypoglycemia,
most of these deaths are thought to be either accidental
(e.g. in traffic) or cardiovascular (e.g. arrhythmia) rather
than the direct consequence of brain death [33, 34].
It should be noted that both the developing brain of
young children with type 1 diabetes [35, 36] and the brain
of the elderly, in particular in patients with type 2 dia-
betes [37, 38], seem more susceptible to harm from
hypoglycemia. Children with type 1 diabetes performed
worse on cognitive tests when they had a history of
severe hypoglycemia below the age of 5 years, compared
to patients without such a history and non-diabetic con-
trols [35]. In prospective cohorts of people with type 2
diabetes, a history of severe hypoglycemia has been
associated with cognitive decline and frank dementia [38],
as well as with greater risks of cardiovascular events and
death [39, 40]. On the cellular level, there are now
indications that glucose deprivation may accelerate
apoptosis of neurons, which could underlie neuronal cell
death and predispose for cognitive decline [41]. It has
also been speculated that the acute, physiological changes
in hematological and hemodynamic parameters induced
by hypoglycemia may be particularly damaging when the
vasculature has already been injured [42, 43], possibly
explaining the discrepancy between type 1 and type 2
diabetes [31, 44]. Another factor explaining this discrep-
ancy may lie in the concept of hypoglycemic
preconditioning. Rodents exposed to recurrent
hypoglycemic events of moderate severity were less likely
to develop neuronal damage or cognitive impairments or
die during subsequent severe hypoglycemia than age-
matched littermates who were not pre-exposed to hypo-
glycemia [45, 46]. These data may help to explain recent
observations that patients with type 1 diabetes and
impaired awareness of hypoglycemia, as a reflection of
recurrent hypoglycemia, appeared not at greater risk of
dying than patients with intact awareness [47].
The role of the brain in glucose counterregulation
The brain is not just at the receiving end of hypoglycemia,
but it plays an important role in both the detection of
hypoglycemia and in the subsequent initiation and coor-
dination of counterregulatory responses to restore
euglycemia, as described above. This system maintains
glucose homeostasis through a classic sensory-motor inte-
grative pathway in which a decrease in plasma glucose
levels is detected by an extended network of glucose
sensing neurons located within the brain and the periphery
[48]. Specialized glucose-sensing cells are located in the
hepatic portal/mesenteric vein, gut, carotid body and oral
cavity. In the brain, glucose-sensing neurons are found at a
number of locations, but particularly in the ventromedial
nucleus of the hypothalamus (VMH) and areas that origi-
nate from the hindbrain. Integrative networks receive
projections from these sensing neurons and subsequently
assimilate their input with signals from other brain regions,
such as information about circadian rhythm and arousal
state. This information is relayed to motor neurons, which
generate an output that drives the counterregulatory
response and subsequently restores plasma glucose levels.
Conversely, glucose sensing may influence other neural
processes that have no role in glucose counterregulatory
function [49].
Although the VMH is only one of a number of regions
involved in the detection of hypoglycemia, it is thought to
be the most important. The VMH serves as the central relay
station for signals from many other regions and plays a
crucial role in the coordination of the counterregulatory
responses to falling glucose levels. Animal studies have
shown that both destruction of the VMH and local perfu-
sion of the VMH with glucose, disrupt counterregulatory
hormone responses to systemic hypoglycemia [50, 51].
Conversely, local glucopenia in the VMH stimulates these
responses in the absence of hypoglycemia [52]. In analogy,
glucose counterregulation was also found defective in a
patient with lesions from sarcoidosis in the hypothalamus,
presumably due to destruction of the glucose-sensing
neurons in the VMH [53].
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The mechanism of glucose sensing by the brain, in
particular in the VMH, has not been fully clarified. Two
main types of glucose-sensing neurons have been identi-
fied: glucose-excited neurons, whose activity increases as
glucose levels rise, and glucose-inhibited neurons, which
become more active as glucose levels fall and less active
when they rise [54]. These neurons ‘sense’ a fall in glucose
probably as a result of alterations in ATP/ADP and AMP/
ATP ratios, respectively, following a reduction in glucose
metabolism. This could explain why fuelling the VMH
with an alternative source of energy, such as lactate, sup-
presses glucose counterregulation [55, 56]. The subsequent
intracellular actions that may ultimately lead to a coun-
terregulatory response probably involve activation of
AMP-activated protein kinase, formation of nitric oxide
and release of glutamate in glucose-inhibited neurons.
Other potential mediators involved in these responses
include (a decrease in) gamma-aminobutyric acid (GABA)
release from glucose-excited neurons, noradrenaline,
serotonin and corticotrophin-releasing hormone [57]. For
further reading on this subject, we refer to recent reviews
by McCrimmon [54] and Chan and Sherwin [57].
Cerebral glucose delivery, uptake and metabolism
Glucose is transported across the blood–brain barrier into
extracellular fluid (ECF) by facilitated diffusion, mediated
via glucose transporter protein 1 (GLUT1) [58]. The pre-
dominant transporters involved in subsequent glucose uptake
from the ECF in neurons and in astrocytes are GLUT3 and
GLUT1, respectively [59], both insulin-independent glucose
transporters. Once intracellular, glucose is phosphorylated by
hexokinase as the initial step of glucose metabolism. The
glucose-6-phosphate (Glc-6-P) thus produced can enter
several metabolic pathways in the brain [60].
In 1945, Kety and Schmidt developed the first method to
quantitatively assess brain glucose uptake in humans in vivo
and to derive data on its subsequent metabolism [61]. This
highly invasive technique required the use of arterial and
internal jugular vein catheterizations to determine arteri-
ovenous concentration differences for glucose, which
together with measurement of global cerebral blood flow
(CBF) were then used to calculate the global cerebral
metabolic rate of glucose [61–64]. In humans, the Kety–
Schmidt method was used to show that brain glucose uptake
falls during hypoglycemia and that this coincides with the
appearance of counterregulatory hormone responses and
autonomic warning symptoms [65, 66]. However, whether
these data can be used to reliably assess brain glucose
metabolism is a matter of debate. Indeed, the calculations
rely solely on the disappearance rate of glucose from the
circulation. Therefore, this technique cannot discriminate
between specific metabolic steps and ignores the potential
contribution of other metabolites. Moreover, the highly
invasive nature of the Kety–Schmidt technique is a con-
siderable limitation for research in humans.
The past 40 years have shown rapid advances in modern
metabolic and functional neuroimaging techniques to study
brain (glucose) metabolism vis-a`-vis CBF during hypo-
glycemia, including positron emission tomography (PET),
functional magnetic resonance imaging (fMRI) and mag-
netic resonance spectroscopy (MRS). It is important to note
that the distribution of CBF and the cerebral metabolic rate
of glucose (CMRglc) are closely linked to local brain activ-
ity. Brain activation causes proportionate increases in both
local CBF and CMRglc. These processes are being referred
to as neurovascular coupling or neurometabolic coupling,
respectively, and hypothesized to be mediated by neuro-
transmitter release and vasoactive metabolic products [67].
Many functional neuroimaging techniques, including fMRI,
rely on neurovascular coupling. The principles of the various
imaging techniques will be briefly discussed (Fig. 1).
PET
Positron emission tomography can be used to measure
emissions from a variety of radioactively labeled tracers in
the brain to quantify CBF, glucose uptake and phospho-
rylation, oxygen consumption and brain receptors for major
neurotransmitters, depending on the type of radiotracer
used [68]. 15O-labeled water PET, for example, has been
commonly applied to quantify regional CBF [69, 70]. For
the study of brain glucose metabolism, [18F]fluoro-2-
deoxy-D-glucose (FDG) is the most widely used tracer.
FDG is taken up by the brain in a similar manner as glu-
cose, but unlike native glucose, once phosphorylated
(FDG-6-P), it cannot be metabolized further, resulting in
accumulation of the tracer in the cell. Under steadystate
conditions, in which total influx of metabolites into a
pathway equals the outflow, the rate of tracer accumulation
in the brain can be used to estimate global and regional
rates of glucose transport and metabolism [58]. PET has
been particularly valuable in studying the effect of hypo-
glycemia on CBF, brain glucose uptake and cerebral
metabolic rate in humans with and without type 1 diabetes
[71–74]. However, this technique cannot be used to study
glucose metabolism downstream of its conversion to glu-
cose-6-phosphate [75]. Also, animal studies suggest that
the lumped constant, a correction factor that relates the
metabolic rate of FDG to that of native glucose [76], may
increase during hypoglycemia [77, 78]. The tracer [11C]3-
O-methyl-D-glucose (3-OMG) may provide more robust
information about cerebral glucose uptake at varying glu-
cose concentrations, as it is not phosphorylated [79], but its
relative short half-life time (*20 min) and complex
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preparation limits the use of this compound in a clinical
setting [80].
fMRI
Functional magnetic resonance imaging is primarily used
to study regional neuronal activation (patterns) by the
detection of changes in oxygen demand by the brain [81],
based on the concept of neurovascular coupling described
above. Blood oxygenation level dependent (BOLD) con-
trast is one of the primary contrast mechanisms for fMRI,
which exploits the differences in magnetic properties
between deoxygenated and oxygenated hemoglobin [82].
Regional brain activation increases local oxygen demands,
but because the consequent increase in CBF exceeds these
demands, the balance between deoxygenated and oxy-
genated hemoglobin changes towards the latter. This
change in hemoglobin oxygenation can be probed and
detected, so that a brain map of regions with increased or
decreased activation can be constructed [81]. fMRI has
been especially useful in detecting brain activation patterns
in response to specific cognitive tasks or visual stimulation.
Hypoglycemia has been reported to reduce regional BOLD
activation in response to these tasks, but less so in patients
with type 1 diabetes [83] than in non-diabetic subjects [84,
85]. These reductions in BOLD responses are commonly
attributed to decreased neuronal activity, yet the potential
impact of hypoglycemia on (global or regional) CBF,
neurovascular coupling or oxidative metabolism, remains
to be determined.
ASL
Arterial spin labeling (ASL) is an MRI method that pro-
vides non-invasive quantification of global and regional
CBF. ASL does not require an exogenous contrast agent,
but uses magnetically labeled arterial blood water as a
diffusible tracer. Arterial blood water is first labeled
magnetically using radiofrequency (RF) pulses. Subse-
quently, this labeled arterial blood flows into the brain
where it exchanges with tissue water, after which an image
is taken. The experiment is then repeated without labeling
the arterial blood to create a control image. The signal
difference between control and labeled images reflects
local CBF [86, 87]. While the signal-to-noise (SNR) ratio
in BOLD fMRI is higher, ASL measures brain perfusion
more directly, enables quantification of CBF, and is suit-
able for studying variations in CBF over a longer period of
time due to stable noise characteristics [88]. ASL thus
allows the detection of changes in CBF during hypo-
glycemia and is, in contrast to fMRI, less dependent on
other metabolic parameters, such as oxygenation or glucose
concentrations that might change during hypoglycemia. A
high magnetic field (e.g. 3 T) is usually recommended to
improve SNR when performing ASL.
MRS
Magnetic resonance spectroscopy is a non-invasive tech-
nique, closely related to MRI. Both techniques make use of
the spin properties of certain nuclei when brought into a
magnetic field. For MRI, the proton nucleus is used to
construct a highly detailed anatomical image based on the
different water concentrations in various tissues. For MRS,
these spin properties are used to determine the
Fig. 1 A simplified illustration of the multiple metabolic pathways of
glucose in the brain and the metabolic signals used in different
neuroimaging techniques. The initial step of glucose metabolism is
phosphorylation of glucose to glucose-6-phosphate (Glc-6-P) by
hexokinase. Glc-6-P can enter several metabolic pathways in the
brain. It can be metabolized to produce energy via glycolysis or the
TCA cycle. Glycolytic and TCA cycle intermediates are also used for
the synthesis of amino acids and neurotransmitters. In addition, Glc-6-
P is a precursor for glycogen. Lastly, metabolism of Glc-6-P via the
pentose phosphate pathway (PPP) provides pentose for nucleotide
synthesis and NADPH, required for reductive reactions, such as lipid
synthesis and for protection against oxidative stress. Arteriovenous
concentration differences (AV dif) can be used to estimate global
cerebral metabolic rate from the disappearance of metabolites from
the circulation. PET (depicted in orange) uses radiolabeled glucose
analogues (such as FDG), which are trapped early in metabolism (for
example fluorodeoxyglucose-6-phosphate/FDG-6-P), to estimate rates
of glucose uptake and metabolism. 31P MRS (depicted in blue)
provides information about ATP production and thus brain energy
metabolism. 13C-MRS (depicted in green) is useful for estimating
TCA cycle fluxes and CMRglc, derived from
13C label incorporation
into specific metabolites (Glu, Gln). Both ASL and BOLD fMRI
provide estimates of CBF
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concentration of specific metabolites in the tissue exam-
ined. These concentrations are derived from the peaks in a
spectrum [89]. MRS is feasible on any nucleus possessing a
magnetic moment, but is most frequently performed on the
high natural abundant and MR sensitive proton nucleus
(1H), providing steady-state information on concentrations
of proton-containing brain metabolites at a single time
point [90]. However, because water contains most of the
proton nuclei, the water signal needs to be suppressed to
allow reliable measurements of metabolite concentrations.
As a consequence, the sensitivity of MRS is manifold
lower than that of MRI, even at high magnetic fields.
Nevertheless, since nearly all metabolites contain protons,
1H-MRS is a powerful technique to identify and quantify a
large number of metabolites relevant for glucose metabo-
lism (e.g. lactate, glutamate, glutamine) at in vivo
concentrations typically above 0.5 mM.
The use of carbon-13 (13C) in MRS is specifically rel-
evant for the study of brain glucose metabolism. Carbon
exists in the human body in two isotopes, of which carbon-
12 (12C) is dominant with a natural abundance of 98.9 %.
12C does not possess a net nuclear spin and consequently
cannot be detected by MRS. In contrast, 13C does possess a
magnetic moment, but has a very low natural abundance of
1.1 %. However, the intravenous infusion of 13C-enriched
substrates, such as [1-13C]glucose, [3-13C]lactate or [3-13-
C]acetate, offers the possibility to study fluxes of these
substrates in the brain through important metabolic path-
ways (Fig. 2).
For the study of brain glucose metabolism, it is impor-
tant to note that [1-13C]glucose is taken up and metabolized
by the brain similar to native (i.e. unlabeled) glucose.
Following transport across the blood–brain barrier and
phosphorylation by hexokinase, glucose is the main sub-
strate for the production of energy (by formation of ATP)
via glycolysis and the tricarboxylic acid (TCA) cycle [82].
As such, 13C-MRS allows the fate of the 13C-labeled glu-
cose to be followed as it flows into glycolysis. The 13C-
label is transferred from glucose on the C-1 position to
pyruvate on the C-3 position during glycolysis and, sub-
sequently, passes through all metabolites of the TCA cycle.
In this process, the 13C-label is incorporated into the MRS-
detectable metabolites glutamate, glutamine and aspartate,
all at specific carbon positions. Because these positions
change during the second time the isotope flows in the
TCA cycle (Fig. 3), the time-course of 13C-label incorpo-
ration into these metabolites can be used as input for a
metabolic model to calculate the TCA cycle flux and
CMRglc [91]. However, although the fates of individual
carbon atoms can be tracked in the TCA cycle, cerebral
13C-MRS provides no information about the loss of label in
diffusible metabolites, such as glutamine and lactate which
may exchange between brain and blood plasma [82, 92].
13C-MRS has been proven to be a valuable imaging
technique to study brain (glucose) metabolism via specific
pathways in humans in vivo, under various conditions,
including hyperglycemia [93] and hypoglycemia [94]. In
addition, 13C labeled compounds other than glucose, such
as 13C-acetate and 13C-lactate, can be used to provide a
more complete picture of the very complex metabolic
processes in the brain. Indeed, 13C-acetate, which is
metabolized almost exclusively in astroglia [95], has been
used to distinguish astroglial and neuronal metabolism
more directly, and to study transport and metabolism of
non-glucose fuels during hypoglycemia [96, 97].
Phosphorus-31 (31P) is another naturally abundant
nucleus with a relatively high sensitivity for MRS. 31P-
MRS of the brain can be used to detect metabolites that
play a key role in brain energy metabolism and provides
information on flux through the creatine kinase reaction
(e.g. ATP, phosphocreatine, inorganic phosphate), intra-
cellular pH and magnesium concentrations [98]. Thus far,
this technique has been seldom used to study brain meta-
bolism during hypoglycemia [99].
Fig. 2 Time series of 13C-MR spectra, acquired from a *125 mL
voxel, placed in the occipital cortex. Spectra are averaged over
20 min, after administration of [1-13C]glucose during a hypoglycemic
clamp in one healthy subject. Once the infused [1-13C]glucose is
taken up by the brain and incorporated into various glucose
metabolites, an increase in signal over time is observed. Numbers
indicate the position of the 13C label, as explained in more detail in
Fig. 3. Asp aspartate, Gln glutamine, Glu glutamate, Lac lactate (from
Ref. [143], with permission from Elsevier)
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Cerebral nutrient transport capacity
and hypoglycemia
Glucose uptake
As mentioned above, glucose uptake into the brain occurs
through facilitated transport independent of insulin. As a
consequence, there is a linear relationship between plasma
glucose concentrations and brain glucose content over a
range of plasma glucose values up to *30 mmol/L [100–
103]. This linear relationship also extends well into the
hypoglycemic range, although data below plasma levels of
*2.5 mmol/L are missing in humans (Fig. 4) [104]. To
explain HAAF, it has been hypothesized that chronic or
repeated hypoglycemia increases glucose transport capac-
ity over the blood–brain barrier to compensate for the fall
in glucose availability to the brain during subsequent
hypoglycemia. Indeed, several animal studies have shown
that days to weeks of chronic hypoglycemia cause upreg-
ulation of brain glucose transporters, including both
GLUT-3 on neuronal membranes [105, 106], and GLUT-1
on the vascular endothelium at the blood–brain barrier
[107, 108]. In accordance, Boyle and co-workers applied
the Kety and Schmidt technique to show preservation of
brain glucose transport rather than a fall during hypo-
glycemia in healthy volunteers after prior exposure to
hypoglycemia, whereas it fell when such exposure had not
taken place [65]. The investigators went on to report sim-
ilar findings of preserved glucose transport in patients with
type 1 diabetes and near-normal glycosylated hemoglobin
(HbA1c), possibly reflecting high hypoglycemic burden, as
they also had reduced awareness of hypoglycemia [66].
In mice and in rats, very low plasma glucose values,
typically well below 2.0 mmol/L, have been found to
proportionally increase brain glucose uptake as a function
of increased cerebral perfusion [102, 109]. Various neu-
roimaging studies investigating glucose transport over the
blood–brain barrier in humans have produced conflicting
results. A 1H-MRS study performed under hyperglycemic
conditions showed greater brain glucose concentrations in
patients with type 1 diabetes and impaired awareness of
hypoglycemia than in people without diabetes [110].
However, a similar study found no evidence of altered
brain glucose transport in healthy volunteers subjected to
antecedent repeated hypoglycemia, despite clearly attenu-
ated hormone responses to hypoglycemia [111]. In
accordance, global blood-to-brain glucose transport, as
measured with [1-11C]-glucose PET, remained unaltered in
Fig. 4 Linear relationship between plasma and brain glucose levels
under normo- and hypoglycemic conditions in healthy subjects (open
squares) and patients with type 1 diabetes (closed circles). Brain
glucose levels were measured with 13C-MRS. The plasma versus
brain glucose relation was fitted with linear regression analysis to
determine reversible Michaelis–Menten kinetics to show the best fit
of the data with 95 % confidence intervals. R2 = 0.59, P\ 0.001.
Assuming continuation of this linear relationship between plasma and
brain glucose levels, brain glucose approaches zero at a plasma
glucose level of approximately 1.2 mmol/L (from Ref. [104], with
permission from the American Diabetes Association)
Fig. 3 One-compartment metabolic model describing the incorpora-
tion of 13C label from (infused) [1-13C]glucose into the TCA cycle
and its metabolites. When taken up by the brain, the 13C-label is first
incorporated into the C3 position of pyruvate and subsequently into
the C3 position of lactate. Once the 13C-label continues through the
TCA cycle, it is incorporated into the C4 position of aKG, glutamate
and glutamine. In the second turn of the cycle, the label is equally
distributed over the C2 and C3 positions of these metabolites. The
TCA cycle flux can be estimated using a metabolic model where the
time courses of the uptake of the 13C-label in glutamate and glutamine
in the different carbon positions, measured with 13C-MRS, are used as
input. Filled circles represent the carbon position that is labeled with
13C, white circles represent unlabeled carbons. aKG a-ketoglutarate,
BBB blood–brain-barrier, Glc glucose, Gln glutamine, Glu glutamate,
Lac lactate, LDH lactate dehydrogenase, Pyr pyruvate, Vgln exchange
rate between glutamate and glutamine, VTCA TCA cycle rate, Vx
exchange rate between a-ketoglutarate and glutamate
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healthy volunteers after exposure to 24 h of moderate
hypoglycemia, albeit interspaced with transient glucose
normalizations during meals [112]. Finally, a 3-OMG-PET
study also showed no differences in global brain glucose
transport during hypoglycemia between patients with nor-
mal and those with impaired awareness of hypoglycemia
[72].
Monocarboxylic acid (MCA) uptake
Although glucose is its principal source of energy, the brain
may resort to alternative non-glucose fuel substrates under
glucopenic conditions. These alternative substrates include
foremost ketones, and lactate, which enter the TCA cycle
after conversion to pyruvate or acetyl coenzyme A, and can
be metabolized in a similar way as glucose to sustain brain
metabolism, and spare glucose.
Ketones such as beta-hydroxybutyrate and acetoacetate
are synthesized in the liver from fatty acids during pro-
longed fasting, starvation and severe carbohydrate
restriction. Under such conditions, up to 60 % of brain
energy requirements may be derived from ketone meta-
bolism [113], whereas ketogenic diets can more or less
restore brain energy metabolism and prevent epileptic
seizures in patients with GLUT1 deficiency who are unable
to transport glucose into the brain [114, 115]. However,
because insulin suppresses the production of ketones, the
brain is usually unable to use this source of energy during
insulin-induced hypoglycemia [116]. PET studies with the
use of both ketone and glucose tracers may help to unravel
the complex interaction between the metabolism of ketones
and glucose by the brain under different circumstances,
including hypoglycemia [113].
In recent years, it has gradually been recognized that
lactate plays an important role in the energy metabolism in
the brain, particularly during hypoglycemia since both
hypoglycemia and insulin increase plasma levels of lactate,
at least in healthy subjects [94, 117, 118]. Under basal,
euglycemic, conditions, the contribution of systemic lactate
to cerebral energy metabolism is approximately 8–10 %.
However, the proportional contribution of lactate has been
reported to increase during strenuous exercise, when
plasma lactate levels rise substantially [119, 120]. The role
of lactate in specific areas of the brain includes its
involvement in or interference with hypoglycemia detec-
tion in the VMH as stated above. Lactate has also been
found to be a crucially monitored variable in the detection
of energy imbalance in the caudal hindbrain [121]. The
importance of lactate for the brain was first highlighted
when Pellerin and Magistretti published their astrocyte-
neuron lactate shuttle (ANLS) hypothesis. This hypothesis
posits that glucose is taken up by and metabolized in
astrocytes to form lactate, after which lactate is exported to
neighboring neurons where it is oxidized, especially during
activation [122]. This concept, which bears analogy to the
cell–cell lactate shuttle, through which skeletal muscle can
transport a non-glucose energy source to other organs
[123], thus suggests that astrocytes play the primary role in
brain glucose metabolism. Simpson et al. later came to a
different conclusion and developed a model that basically
adopts the opposite view, in which neurons are the prin-
cipal site of glucose uptake and metabolism, and the chief
exporter of lactate. This hypothesis was therefore termed
the neuron-astrocyte lactate shuttle (NALS) [59] and
fuelled a heavy debate [124, 125]. The debate on the
direction of the lactate shuttle is ongoing with studies
identifying the neuron as the principal locus of glucose
uptake [126], and other studies indicating that neurons
rather than astrocytes are the primary sites for oxidation of
exogenous lactate [119, 127].
Monocarboxylic acid transporters (MCTs) facilitate the
uptake of lactate as well as that of acetate and ketone
bodies into the brain, the expression of which may increase
following sustained hyperketonemia or recurrent hypo-
glycemia. A recent study in rats demonstrated a twofold
increase in the expression of MCTs 1 and 2 in the cerebral
cortex after the induction of diabetes by streptozotocin.
After 8 weeks of frequent, prolonged endurance training
and concomitant exposure to hypoglycemia after and
between exercise sessions, the expression of both trans-
porters increased even further [128]. Such greater transport
capacity may explain recent observations in which recur-
rent exposure to hypoglycemia increased the uptake of 13C-
labeled lactate into the rat brain under hypoglycemic
conditions [129]. During hypoglycemia, the uptake of both
acetate and lactate into the human brain, as measured by
13C-MRS during infusion of 13C-labeled acetate or lactate,
respectively, was found to be considerably greater in
patients with well-controlled type 1 diabetes than in heal-
thy controls [97, 130].
Transport and uptake of other substrates
Oral intake of amino acids has been reported to enhance the
glucagon response to hypoglycemia and to improve some
aspects of cognitive function during hypoglycemia in non-
diabetic and diabetic subjects [131, 132]. Amino acids
might also serve as a non-glucose substrate that could be
used by the brain as an alternative fuel and to sustain
cognitive function during hypoglycemia. Early studies
showing utilization of amino acids by the rat brain during
prolonged hypoglycemia and of amino acids contributing
to glycogen synthesis in brain cell cultures supported this
theory [133, 134]. However, data obtained in humans using
arteriovenous concentration differences found no evidence
that greater availability of amino acids increased its net
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brain uptake during hypoglycemia [135] or was able to
offset energy deficit due to reduced glucose supply [136].
A few studies have investigated whether the human
brain can use lipid substrates to support cerebral metabo-
lism and brain function during hypoglycemia. Fatty acids
can readily cross the blood–brain barrier to be oxidized by
the brain, as demonstrated by a 13C-MRS study in rats
[137]. In healthy humans, elevated plasma levels of non-
esterified fatty acids and glycerol were found to reduce
hormonal and symptom responses to hypoglycemia, but
could not protect against the fall in cognitive function
[138]. Conversely, in a more recent study, ingestion of
medium-chain triglycerides maintained cognitive function
during hypoglycemia without affecting adrenergic or
symptomatic responses to hypoglycemia in intensively
treated subjects with type 1 diabetes [139]. It should be
acknowledged, however, that the inferences made with
respect to the uptake of lipid substrates in the brain were
indirect and that no neuroimaging studies have been per-
formed that evaluated the effects of these substances on
cerebral metabolism more directly.
Brain metabolism during hypoglycemia
Glucose metabolism
Both PET and MRS have been used to investigate the
effect of hypoglycemia on brain glucose metabolism. PET
has been particularly useful in detecting regional differ-
ences in tracer accumulation in the brain, both during
hypoglycemia [71], and after restoration to euglycemia
[74]. However, rather than focusing on glucose uptake or
metabolism, the close link with neuronal activation is then
exploited to use the data as input factors for mapping
regional brain activity. Thus, the observation that CMRglc
relatively increased during hypoglycemia in patients with
type 1 diabetes and normal awareness of hypoglycemia,
and relatively fell in patients with impaired awareness of
hypoglycemia, was interpreted as an increase in brain
activation and absence of such a response [72]. When this
increased activation would occur in brain areas involved in
the perception of and the generation of responses to
hypoglycemia, the lack of increased activation could then
underlie loss of hypoglycemic awareness [72, 140]. Sup-
port for this hypothesis came from another FDG-PET study
[141] and a subsequent analysis of these data [73], as tracer
uptake in areas that engage appetite control and food-
seeking behavior was reduced in patients with impaired
compared to patients with intact awareness of
hypoglycemia.
As outlined above, 13C-MRS in combination with
infusion of 13C-labeled glucose has the unique property
that it enables the investigation of cerebral glucose meta-
bolism in humans in vivo. Since the SNR is relatively low,
most studies employing this technique used large doses of
isotopically enriched glucose at high enrichment percent-
ages. Measurements have consequently generally been
performed under hyperglycemic conditions with glucose
levels up to 17 mmol/L and plasma C-13 enrichment val-
ues exceeding 60 %. Under such conditions, Henry et al.
[93] reported no differences in the TCA cycle rate between
patients with type 1 diabetes with impaired awareness of
hypoglycemia and healthy controls. More recently, an
improved sensitivity of the 13C-MRS method [142] in
combination with an optimized 13C-glucose infusion pro-
tocol enabled us to study glucose metabolism in the human
brain during hypoglycemia at lower enrichment values
[143]. With this optimized technique, no differences were
observed in cerebral glucose metabolism between hypo-
glycemia and euglycemia, neither in healthy controls [94],
nor in patients with type 1 diabetes [144]. Under hypo-
glycemic conditions, however, the TCA cycle rate was
approximately 45 % higher in patients than in healthy
subjects, and inversely related to HbA1c. Appreciating a
low HbA1c as a proxy for a high hypoglycemic burden,
these data suggested a role for prior hypoglycemic expo-
sure in the higher TCA cycle rate in patients with type 1
diabetes. Differences in brain glucose levels did not explain
the preservation of brain metabolism and the higher TCA
cycle rate in the patients, which suggested influx of a non-
glucose carbohydrate source [104]. In an animal study by
Herzog et al. [129], brain glucose transport capacity during
hypoglycemia became rate limiting for TCA cycle activity
in control animals, but not in rats exposed to antecedent
recurrent hypoglycemia. Explanations for the discrepancy
between the human and rodent data include the different
species and the fact that the hypoglycemic condition was
more profound in the animals. Indeed, studies in mice
suggest that intracellular brain glucose concentrations
approach depletion at plasma glucose values between 2 and
3 mmol/L [109].
Glycogen metabolism
The brain is able to store glycogen and to use this com-
pound when plasma glucose levels are low, although its
capacity to do so is very limited compared to other tissues
such as skeletal muscle and the liver. It was long assumed
that this presence of glycogen was restricted to astrocytes.
However, a recent study showed that neurons contain a low
but measurable amount of glycogen, the use of which was
found to protect against hypoxic stress, at least in neuronal
cell cultures and animal models [145]. Both in rodents
[146] and in humans [147], it was shown that brain
glycogen was used during hypoglycemia, and that its stores
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were replenished above baseline levels after restoration of
euglycemia, a phenomenon termed glycogen supercom-
pensation. It has been speculated that this expanded source
of glucose within the brain could contribute to the devel-
opment of impaired awareness of hypoglycemia by fuelling
the brain or at least those areas involved in glucose-sensing
during subsequent hypoglycemia [146]. However, prior
exposure to recurrent hypoglycemia neither facilitated nor
impaired access to glucose from glycogen in the rat brain
during subsequent hypoglycemia [148]. Additionally, brain
glycogen content, as measured by 13C-MRS in conjunction
with 13C-glucose administration, was lower rather than
higher in patients with type 1 diabetes and hypoglycemia
unawareness [149].
Glutamate metabolism
Glutamate is the major excitatory neurotransmitter in the
brain, but has many other metabolic fates, including the
formation of glutamine, GABA and glutathione [150]. In
addition, a new concept has been introduced by Sonnewald
[151], who proposed that glutamate degradation in astro-
cytes contributes to most of the lactate that is released from
the brain under resting conditions, offering a novel expla-
nation for the concept of aerobic glycolysis in the resting
state [151, 152]. Lastly, glutamate can be oxidized for the
production of energy [150]. To this end, glutamate pro-
duction in the brain is tightly coupled to TCA cycle activity
[153]. Using 1H-MRS, Bischof et al. reported that hypo-
glycemia reduced the cerebral glutamate to creatine ratio in
healthy controls, but not in patients with type 1 diabetes
[154]. Similar results were reported by a more recent 1H-
MRS study, were hypoglycemia reduced brain glutamate
levels in healthy controls and in patients with type 1 dia-
betes with normal hypoglycemic awareness, but not in
patients with impaired awareness of hypoglycemia [155].
The authors concluded that the preservation of brain glu-
tamate during hypoglycemia in the latter group reflected a
metabolic adaptation that eliminated the need to oxidize
glutamate. They speculated that this adaptation could be
augmented transport of glucose or of alternative fuels to the
brain.
Metabolism of monocarboxylic acids
As discussed earlier, MRS studies using 13C-labelled
acetate and lactate have clearly suggested that the capacity
to transport MCAs over the blood–brain barrier during
hypoglycemia is increased in patients with well-controlled
type 1 diabetes. Indeed, a study during which 13C-acetate
was infused under hypoglycemic conditions showed more
than twofold higher brain acetate concentrations in subjects
with type 1 diabetes compared to healthy controls. This
greater acetate availability translated into a fraction of
oxidative metabolism that resulted from acetate to be
similarly increased [97]. In accordance, the relative con-
tribution of acetate to brain metabolism in rats exposed to
recurrent antecedent hypoglycemia was also increased
during next-day hypoglycemia, indicating that brain sub-
strate preferences may change rapidly from glucose to
alternative substrates if needed [156]. To delineate whether
this effect was a function of diabetes, prior hypoglycemia
or both, the investigators repeated their 13C-acetate study in
patients with type 1 diabetes with normal or impaired
awareness of hypoglycemia and in healthy controls. They
found that absolute rates of acetate metabolism during
hypoglycemia were only higher in the patients with
impaired awareness of hypoglycemic, suggesting that
changes in acetate metabolism are the consequence of prior
exposure to hypoglycemia rather than of diabetes per se
[96].
Lactate uses the same MCT as acetate to cross the
blood–brain barrier. Since plasma levels of lactate are
approximately tenfold higher than those of acetate, and
hypoglycemia stimulates the production of lactate [117], it
seems plausible that lactate is the more likely substrate for
brain metabolism when glucose levels are low. Studies
dating back to the 1990s have shown that exogenous
administration of lactate attenuates counterregulatory
responses to and preserves cognitive function during
hypoglycemia, presumably because lactate is used as an
alternative source of energy by the brain [157–160]. In
agreement, brain lactate concentrations during hypo-
glycemia, derived from the cerebral uptake of 13C-labelled
lactate, were several fold higher in patients with type 1
diabetes with a history of frequent hypoglycemic episodes
than in non-diabetic subjects [130] and in rats exposed to
recurrent hypoglycemia versus those not exposed [129].
Surprisingly, the authors found no indication of greater
lactate oxidation, as reflected by unchanged 13C fractional
enrichments of brain glutamate and glutamine [130]. Data
from the rodent study, in which lower glucose levels were
achieved than in the human study, suggested that prior
hypoglycemic exposure increased both the uptake and the
oxidation of glucose by the brain, despite the higher lactate
levels [129]. However, when the animal brain was stimu-
lated during hypoglycemia, animals exposed to recurrent
hypoglycemia had a partial loss of their functional cortical
response, which was only normalized after the adminis-
tration of lactate. This suggests that the higher capacity for
lactate transport only becomes critical when the brain is
activated during (deep) hypoglycemia.
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Cerebral blood flow and hypoglycemia
There is uncertainty as to whether hypoglycemia affects
global CBF and in what direction. Previous research in
both patients with type 1 diabetes and healthy controls has
reported either no change in global CBF during hypo-
glycemia [65, 66, 136], a modest increase [161–163], or
even a slight decrease [71]. Differences in the plasma
glucose levels achieved during hypoglycemia and, more
importantly, in imaging techniques probably explain many
of the discrepancies. Studies that investigated the effect of
hypoglycemia on regional relative changes in CBF seem to
have produced more consistent data. Both in healthy con-
trols [161] and in patients with type 1 diabetes [164],
hypoglycemia was found to increase blood flow to the
frontal lobes. This relative redistribution of regional CBF
was already observed under euglycemic conditions in
patients with type 1 diabetes, and was more pronounced in
patients who had experienced frequent hypoglycemia
[165]. Since the frontal lobes are among the most vulner-
able brain areas to suffer structural damage, this may be an
adaptive response to prevent such damage by maintaining
fuel supply during subsequent hypoglycemia.
Hypoglycemia has also been found to increase CBF in
the thalamus [71, 166, 167] and hypothalamus [168, 169].
Mild or moderate hypoglycemia caused a rise in CBF in the
hypothalamus in healthy non-diabetic subjects, as assessed
by fMRI [168] or ASL [169], which preceded the rise in
counterregulatory hormone responses seen during hypo-
glycemia [169]. Interestingly, Mangia et al. found blunting
of this increase in thalamic perfusion during hypoglycemia
in patients with type 1 diabetes with hypoglycemia
unawareness, and a correlation between thalamic perfusion
and the adrenaline response to hypoglycemia [167]. In
contrast, recurrent hypoglycemia enhanced, rather than
decreased, thalamic perfusion during subsequent hypo-
glycemia in healthy controls [170], so that the role of this
brain region in the adaptation to hypoglycemia remains
uncertain.
Discussion
The scientific field of metabolic and functional neu-
roimaging techniques for the brain has tremendously
progressed over the past couple of decades. The application
of these techniques to hypoglycemia research has consid-
erably advanced our understanding of the brain’s responses
to hypoglycemia. As plasma glucose falls below levels that
can be reversed by responses at the level of pancreatic
islets, i.e. suppression of insulin release and stimulation of
that of glucagon, the brain’s sensing abilities are activated
to allow timely detection of hypoglycemia. Data from
functional and metabolic neuroimaging techniques now
suggest that such moderate hypoglycemia neither affects
the perfusion to nor the uptake of glucose into the brain, at
least not globally, unless much deeper levels of glucose are
achieved [102, 109]. In accordance, cerebral glucose
metabolism appears largely maintained during moderate
hypoglycemia [94, 129, 144]. However, on the regional
level, moderate hypoglycemia causes redistribution of CBF
to various brain areas involved in the detection of hypo-
glycemia, particularly the (hypo)thalamus [71, 166–169],
where enhanced neuronal activation stimulates glucose
uptake and metabolism. Such enhanced neuronal activation
has also been found to occur in brain areas involved in
appetitive motivational networks [73], thus linking the
detection of hypoglycemia to a behavioral response.
Modern neuroimaging studies have revealed that
recurrent hypoglycemia, which typically affects people
with type 1 diabetes and underlies the clinical syndrome of
impaired awareness of hypoglycemia, may initiate cerebral
adaptations at many different levels. First, there is inter-
ference with the accurate detection of hypoglycemia,
probably occurring at the level of the VMH. Brain areas
that control appetite and induce fear and anxiety may not
become activated during hypoglycemia. Whether locally
increased glucose uptake in or reduced neuronal activation
of the hypothalamic area (or both) form the underlying
mechanism remains to be revealed. Importantly, it should
be acknowledged that neurovascular coupling may be
altered as a consequence of diabetes per se [171], chronic
hyperglycemia [172] or microangiopathy [173], thus lim-
iting the interpretation of studies relying on this concept.
There is conflicting evidence as to whether recurrent
hypoglycemia can stimulate brain glucose uptake during
hypoglycemia [65, 66], although most studies employing
neuroimaging techniques found no evidence for this sug-
gestion [72, 111, 112]. Nevertheless, patients with type 1
diabetes, particularly those with impaired awareness of
hypoglycemia [155], seem better able in maintaining brain
(glucose) metabolism during hypoglycemia than healthy
controls [94, 144, 154, 155], probably as a consequence of
prior hypoglycemia [144]. Since profound hypoglycemia
will eventually cause brain glucose metabolism to deteri-
orate [129], such an adaptation may shift the threshold for
deterioration of the metabolic rate to lower plasma glucose
levels.
Several mechanisms have been proposed that could
explain the discrepancy between hypoglycemia-induced
preservation of cerebral glucose metabolism and the fall in
glucose availability during hypoglycemia. It seems likely
that influx of a non-glucose energy substrate plays a role.
Recent (neuroimaging) studies found little evidence to
support enhanced blood to brain transport of amino acids
[135, 136] or lipid substrates transport [138, 139] and
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ketones are unlikely candidates because its production is
suppressed by insulin. Also, the lower brain glycogen
content in patients with type 1 diabetes with impaired
awareness of hypoglycemia compared to controls [149]
argues strongly against the glycogen supercompensation
hypothesis. Several arguments suggest a major role for
lactate in preserving brain glucose metabolism during
hypoglycemia. These include: (1) lactate can be used by
the brain and may even be preferred over glucose under
non-hypoglycemic conditions [174, 175]; (2) the capacity
for lactate transport over the blood–brain barrier is
increased in patients with impaired awareness of hypo-
glycemia and in rats after exposure to hypoglycemia [97,
129]; (3) the use of lactate by glucose-sensing neurons in
the VMH may interfere with hypoglycemia sensing [54, 56,
57]. However, there are data that suggest that lactate is not
used as major energy source for the brain during moderate
hypoglycemia, despite greater availability [129, 130]. Also,
it is not yet known whether brain uptake or metabolism of
endogenously produced lactate is increased during hypo-
glycemia in patients with type 1 diabetes and impaired
awareness of hypoglycemia. Finally, it has been suggested
that lactate may serve as a metabolic regulator or inter-
cellular signaling molecule rather than a fuel, modulating
brain glucose metabolism, oxygen delivery and CBF [176,
177]. Mechanisms by which lactate might exert this effect
[178] include modulation of prostaglandin action (and thus
CBF) [177, 179], adjustment of the NADH/NAD? redox
ratio [123], and the regulation of neuronal cAMP formation
via the lactate receptor G-protein-coupled receptor 81
(GPR81) [180].
Conclusion
Hypoglycemia is the principal barrier for achieving opti-
mal, let alone normal, glycemic control for indefinite
periods of time in patients with type 1 diabetes and
advanced insulin-requiring type 2 diabetes [181]. Recur-
rent hypoglycemia forms the basis of HAAF and the
clinical syndrome of impaired awareness of hypoglycemia
by attenuating physiological defenses against subsequent
hypoglycemia, consequently increasing the risk for severe
hypoglycemia. Paradoxically, the mechanism(s) underly-
ing these glucose counterregulatory impairments may be
related to, or even caused by, processes that are seem-
ingly aimed at protecting the brain against harm from
severe hypoglycemia. The progress in metabolic and
functional neuroimaging techniques has revealed that
recurrent hypoglycemia causes cerebral adaptations to
occur on many different levels. These adaptations include
those in the regional delivery (blood flow) and transport
of glucose to the brain, the handling of glucose by the
brain and that of non-glucose alternative fuels, as well as
activation or de-activation of brain areas involved in
behavioral responses. It remains to be elucidated whether,
and if so under which circumstances and in which brain
areas, the brain uses non-glucose alternative sources of
energy, particularly lactate, and whether this contributes
to the emergence of impaired awareness of hypoglycemia.
Such information is needed first to foster personalized
decision-making with respect to glycemic targets, but
should eventually lead to treatments that eliminate
hypoglycemia from the lives of people with type 1 dia-
betes without compromising glucose control.
Acknowledgments We are indebted to Prof. A. Heerschap for his
helpful advice. This work was financially supported by the Dutch
Diabetes Research Foundation and the European Foundation for the
Study of Diabetes (EFSD).
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Clarke DD, Sokoloff L (1999) Circulation and energy metabo-
lism of the brain. In: Siegel GJ, Agrafnoff BW, Albers RW,
Molinoff SK, Fisher PB, Uhler MD (eds) Basic neurochemistry:
molecular, cellular and medical aspects, 6th edn. Lippincott-
Raven, Philadelphia
2. (1993) The effect of intensive treatment of diabetes on the
development and progression of long-term complications in
insulin-dependent diabetes mellitus. The Diabetes Control and
Complications Trial Research Group. N Engl J Med
329(14):977–986. doi:10.1056/NEJM199309303291401
3. Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S,
Hougaard P, Thorsteinsson B (2001) Activity of angiotensin-
converting enzyme and risk of severe hypoglycaemia in type 1
diabetes mellitus. Lancet 357(9264):1248–1253. doi:10.1016/
S0140-6736(00)04405-6
4. Pedersen-Bjergaard U, Pramming S, Heller SR, Wallace TM,
Rasmussen AK, Jorgensen HV, Matthews DR, Hougaard P,
Thorsteinsson B (2004) Severe hypoglycaemia in 1076 adult
patients with type 1 diabetes: influence of risk markers and
selection. Diabetes Metab Res Rev 20(6):479–486. doi:10.1002/
dmrr.482
5. Ostenson CG, Geelhoed-Duijvestijn P, Lahtela J, Weitgasser R,
Markert Jensen M, Pedersen-Bjergaard U (2014) Self-reported
non-severe hypoglycaemic events in Europe. Diabet Med
31(1):92–101. doi:10.1111/dme.12261
6. ter Braak EW, Appelman AM, van de Laak M, Stolk RP, van
Haeften TW, Erkelens DW (2000) Clinical characteristics of
type 1 diabetic patients with and without severe hypoglycemia.
Diabetes Care 23(10):1467–1471
7. Group UKHS (2007) Risk of hypoglycaemia in types 1 and 2
diabetes: effects of treatment modalities and their duration.
Diabetologia 50(6):1140–1147. doi:10.1007/s00125-007-0599-y
716 H. M. M. Rooijackers et al.
123
8. Gonder-Frederick LA, Cox DJ, Driesen NR, Ryan CM, Clarke
WL (1994) Individual differences in neurobehavioral disruption
during mild and moderate hypoglycemia in adults with IDDM.
Diabetes 43(12):1407–1412
9. Cryer PE (2013) Mechanisms of hypoglycemia-associated
autonomic failure in diabetes. N Engl J Med 369(4):362–372.
doi:10.1056/NEJMra1215228
10. Cryer PE (2008) The barrier of hypoglycemia in diabetes.
Diabetes 57(12):3169–3176. doi:10.2337/db08-1084
11. Tesfaye N, Seaquist ER (2010) Neuroendocrine responses to
hypoglycemia. Ann N Y Acad Sci 1212:12–28. doi:10.1111/j.
1749-6632.2010.05820.x
12. Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH
(1973) Lack of glucagon response to hypoglycemia in diabetes:
evidence for an intrinsic pancreatic alpha cell defect. Science
182(4108):171–173
13. Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV (1988)
Effect of intensive insulin therapy on glycemic thresholds for
counterregulatory hormone release. Diabetes 37(7):901–907
14. Fritsche A, Stefan N, Haring H, Gerich J, Stumvoll M (2001)
Avoidance of hypoglycemia restores hypoglycemia awareness
by increasing beta-adrenergic sensitivity in type 1 diabetes. Ann
Intern Med 134(9 Pt 1):729–736
15. Dagogo-Jack S, Rattarasarn C, Cryer PE (1994) Reversal of
hypoglycemia unawareness, but not defective glucose counter-
regulation, in IDDM. Diabetes 43(12):1426–1434
16. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S,
Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R
(2013) Hypoglycemia and diabetes: a report of a workgroup of
the American Diabetes Association and the Endocrine Society.
Diabetes Care 36(5):1384–1395. doi:10.2337/dc12-2480
17. Geddes J, Schopman JE, Zammitt NN, Frier BM (2008)
Prevalence of impaired awareness of hypoglycaemia in adults
with Type 1 diabetes. Diabet Med 25(4):501–504. doi:10.1111/j.
1464-5491.2008.02413.x
18. Schopman JE, Geddes J, Frier BM (2010) Prevalence of
impaired awareness of hypoglycaemia and frequency of hypo-
glycaemia in insulin-treated type 2 diabetes. Diabetes Res Clin
Pract 87(1):64–68. doi:10.1016/j.diabres.2009.10.013
19. Dagogo-Jack SE, Craft S, Cryer PE (1993) Hypoglycemia-as-
sociated autonomic failure in insulin-dependent diabetes
mellitus. Recent antecedent hypoglycemia reduces autonomic
responses to, symptoms of, and defense against subsequent
hypoglycemia. J Clin Invest 91(3):819–828. doi:10.1172/
JCI116302
20. Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA (1994)
Restoration of hypoglycaemia awareness in patients with long-
duration insulin-dependent diabetes. Lancet 344(8918):283–287
21. Fanelli CG, Epifano L, Rambotti AM, Pampanelli S, Di Vin-
cenzo A, Modarelli F, Lepore M, Annibale B, Ciofetta M,
Bottini P et al (1993) Meticulous prevention of hypoglycemia
normalizes the glycemic thresholds and magnitude of most of
neuroendocrine responses to, symptoms of, and cognitive
function during hypoglycemia in intensively treated patients
with short-term IDDM. Diabetes 42(11):1683–1689
22. Zammitt NN, Warren RE, Deary IJ, Frier BM (2008) Delayed
recovery of cognitive function following hypoglycemia in adults
with type 1 diabetes: effect of impaired awareness of hypo-
glycemia. Diabetes 57(3):732–736. doi:10.2337/db07-0695
23. Graveling AJ, Deary IJ, Frier BM (2013) Acute hypoglycemia
impairs executive cognitive function in adults with and without
type 1 diabetes. Diabetes Care 36(10):3240–3246. doi:10.2337/
dc13-0194
24. Inkster B, Frier BM (2012) The effects of acute hypoglycaemia
on cognitive function in type 1 diabetes. Br J Diabetes Vasc Dis
12(5):221–226
25. Tkacs NC, Dunn-Meynell AA, Levin BE (2000) Presumed
apoptosis and reduced arcuate nucleus neuropeptide Y and pro-
opiomelanocortin mRNA in non-coma hypoglycemia. Diabetes
49(5):820–826
26. Ennis K, Tran PV, Seaquist ER, Rao R (2008) Postnatal age
influences hypoglycemia-induced neuronal injury in the rat brain.
Brain Res 1224:119–126. doi:10.1016/j.brainres.2008.06.003
27. Auer RN, Wieloch T, Olsson Y, Siesjo BK (1984) The distri-
bution of hypoglycemic brain damage. Acta Neuropathol
64(3):177–191
28. Ma JH, Kim YJ, Yoo WJ, Ihn YK, Kim JY, Song HH, Kim BS
(2009) MR imaging of hypoglycemic encephalopathy: lesion
distribution and prognosis prediction by diffusion-weighted
imaging. Neuroradiology 51(10):641–649. doi:10.1007/s00234-
009-0544-5
29. Kang EG, Jeon SJ, Choi SS, Song CJ, Yu IK (2010) Diffusion
MR imaging of hypoglycemic encephalopathy. AJNR Am J
Neuroradiol 31(3):559–564. doi:10.3174/ajnr.A1856
30. Yoneda Y, Yamamoto S (2005) Cerebral cortical laminar
necrosis on diffusion-weighted MRI in hypoglycaemic
encephalopathy. Diabet Med 22(8):1098–1100. doi:10.1111/j.
1464-5491.2005.01568.x
31. Jacobson AM, Musen G, Ryan CM, Silvers N, Cleary P,
Waberski B, Burwood A, Weinger K, Bayless M, Dahms W,
Harth J (2007) Long-term effect of diabetes and its treatment on
cognitive function. N Engl J Med 356(18):1842–1852. doi:10.
1056/NEJMoa066397
32. Nathan DM, Group DER (2014) The diabetes control and
complications trial/epidemiology of diabetes interventions and
complications study at 30 years: overview. Diabetes Care
37(1):9–16. doi:10.2337/dc13-2112
33. Skrivarhaug T, Bangstad HJ, Stene LC, Sandvik L, Hanssen KF,
Joner G (2006) Long-term mortality in a nationwide cohort of
childhood-onset type 1 diabetic patients in Norway. Diabetolo-
gia 49(2):298–305. doi:10.1007/s00125-005-0082-6
34. Patterson CC, Dahlquist G, Harjutsalo V, Joner G, Feltbower
RG, Svensson J, Schober E, Gyurus E, Castell C, Urbonaite B,
Rosenbauer J, Iotova V, Thorsson AV, Soltesz G (2007) Early
mortality in EURODIAB population-based cohorts of type 1
diabetes diagnosed in childhood since 1989. Diabetologia
50(12):2439–2442. doi:10.1007/s00125-007-0824-8
35. Perantie DC, Lim A, Wu J, Weaver P, Warren SL, Sadler M,
White NH, Hershey T (2008) Effects of prior hypoglycemia and
hyperglycemia on cognition in children with type 1 diabetes
mellitus. Pediatr Diabetes 9(2):87–95. doi:10.1111/j.1399-5448.
2007.00274.x
36. Lin A, Northam EA, Rankins D, Werther GA, Cameron FJ
(2010) Neuropsychological profiles of young people with type 1
diabetes 12 yr after disease onset. Pediatr Diabetes
11(4):235–243. doi:10.1111/j.1399-5448.2009.00588.x
37. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV
(2009) Hypoglycemic episodes and risk of dementia in older
patients with type 2 diabetes mellitus. JAMA
301(15):1565–1572. doi:10.1001/jama.2009.460
38. Yaffe K, Falvey CM, Hamilton N, Harris TB, Simonsick EM,
Strotmeyer ES, Shorr RI, Metti A, Schwartz AV, Health ABCS
(2013) Association between hypoglycemia and dementia in a
biracial cohort of older adults with diabetes mellitus. JAMA
Intern Med 173(14):1300–1306. doi:10.1001/jamainternmed.
2013.6176
39. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L,
Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE,
Kengne AP, Marre M, Heller S, ADVANCE Collaborative
Group (2010) Severe hypoglycemia and risks of vascular events
and death. N Engl J Med 363(15):1410–1418. doi:10.1056/
NEJMoa1003795
Brain glucose metabolism during hypoglycemia in type 1 diabetes: insights from… 717
123
40. Goto A, Arah OA, Goto M, Terauchi Y, Noda M (2013) Severe
hypoglycaemia and cardiovascular disease: systematic review
and meta-analysis with bias analysis. BMJ 347:f4533. doi:10.
1136/bmj.f4533
41. Mergenthaler P, Kahl A, Kamitz A, van Laak V, Stohlmann K,
Thomsen S, Klawitter H, Przesdzing I, Neeb L, Freyer D, Priller
J, Collins TJ, Megow D, Dirnagl U, Andrews DW, Meisel A
(2012) Mitochondrial hexokinase II (HKII) and phosphoprotein
enriched in astrocytes (PEA15) form a molecular switch gov-
erning cellular fate depending on the metabolic state. Proc Natl
Acad Sci USA 109(5):1518–1523. doi:10.1073/pnas.
1108225109
42. Wright RJ, Frier BM (2008) Vascular disease and diabetes: is
hypoglycaemia an aggravating factor? Diabetes Metab Res Rev
24(5):353–363. doi:10.1002/dmrr.865
43. Rana O, Byrne CD, Kerr D, Coppini DV, Zouwail S, Senior R,
Begley J, Walker JJ, Greaves K (2011) Acute hypoglycemia
decreases myocardial blood flow reserve in patients with type 1
diabetes mellitus and in healthy humans. Circulation
124(14):1548–1556. doi:10.1161/CIRCULATIONAHA.110.
992297
44. Gruden G, Barutta F, Chaturvedi N, Schalkwijk C, Stehouwer
CD, Witte DR, Fuller JH, Perin PC, Bruno G (2012) Severe
hypoglycemia and cardiovascular disease incidence in type 1
diabetes: the EURODIAB Prospective Complications Study.
Diabetes Care 35(7):1598–1604. doi:10.2337/dc11-1531
45. Puente EC, Silverstein J, Bree AJ, Musikantow DR, Wozniak
DF, Maloney S, Daphna-Iken D, Fisher SJ (2010) Recurrent
moderate hypoglycemia ameliorates brain damage and cognitive
dysfunction induced by severe hypoglycemia. Diabetes
59(4):1055–1062. doi:10.2337/db09-1495
46. Reno CM, Daphna-Iken D, Chen YS, VanderWeele J, Jethi K,
Fisher SJ (2013) Severe hypoglycemia-induced lethal cardiac
arrhythmias are mediated by sympathoadrenal activation. Dia-
betes 62(10):3570–3581. doi:10.2337/db13-0216
47. Sejling AS, Schouwenberg B, Faerch LH, Thorsteinsson B, de
Galan BE, Pedersen-Bjergaard U (2015) Association between
hypoglycaemia and impaired hypoglycaemia awareness and
mortality in people with Type 1 diabetes mellitus. Diabet Med.
doi:10.1111/dme.12810
48. Donovan CM, Watts AG (2014) Peripheral and central glucose
sensing in hypoglycemic detection. Physiology (Bethesda)
29(5):314–324. doi:10.1152/physiol.00069.2013
49. Watts AG, Donovan CM (2010) Sweet talk in the brain: glu-
cosensing, neural networks, and hypoglycemic
counterregulation. Front Neuroendocrinol 31(1):32–43. doi:10.
1016/j.yfrne.2009.10.006
50. Borg WP, During MJ, Sherwin RS, Borg MA, Brines ML,
Shulman GI (1994) Ventromedial hypothalamic lesions in rats
suppress counterregulatory responses to hypoglycemia. J Clin
Invest 93(4):1677–1682. doi:10.1172/JCI117150
51. Borg MA, Sherwin RS, Borg WP, Tamborlane WV, Shulman GI
(1997) Local ventromedial hypothalamus glucose perfusion
blocks counterregulation during systemic hypoglycemia in
awake rats. J Clin Invest 99(2):361–365. doi:10.1172/JCI119165
52. Borg WP, Sherwin RS, During MJ, Borg MA, Shulman GI
(1995) Local ventromedial hypothalamus glucopenia triggers
counterregulatory hormone release. Diabetes 44(2):180–184
53. Fery F, Plat L, van de Borne P, Cogan E, Mockel J (1999)
Impaired counterregulation of glucose in a patient with
hypothalamic sarcoidosis. N Engl J Med 340(11):852–856.
doi:10.1056/NEJM199903183401105
54. McCrimmon R (2009) Glucose sensing during hypoglycemia:
lessons from the lab. Diabetes Care 32(8):1357–1363. doi:10.
2337/dc09-0123
55. BorgMA,TamborlaneWV,ShulmanGI, SherwinRS (2003)Local
lactate perfusion of the ventromedial hypothalamus suppresses
hypoglycemic counterregulation. Diabetes 52(3):663–666
56. Chan O, Paranjape SA, Horblitt A, Zhu W, Sherwin RS (2013)
Lactate-induced release of GABA in the ventromedial
hypothalamus contributes to counterregulatory failure in recur-
rent hypoglycemia and diabetes. Diabetes 62(12):4239–4246.
doi:10.2337/db13-0770
57. Chan O, Sherwin R (2013) Influence of VMH fuel sensing on
hypoglycemic responses. Trends Endocrinol Metab
24(12):616–624. doi:10.1016/j.tem.2013.08.005
58. Dienel GA (2012) Fueling and imaging brain activation. ASN
Neuro 4(5). doi:10.1042/AN20120021
59. Simpson IA, Carruthers A, Vannucci SJ (2007) Supply and
demand in cerebral energy metabolism: the role of nutrient
transporters. J Cereb Blood Flow Metab 27(11):1766–1791.
doi:10.1038/sj.jcbfm.9600521
60. Wilson JE (2003) Isozymes of mammalian hexokinase: struc-
ture, subcellular localization and metabolic function. J Exp Biol
206(Pt 12):2049–2057
61. Kety SS, Schmidt CF (1945) The determination of cerebral
blood flow in man by the use of nitrous oxide in low concen-
trations. Am J Phsyiol 143:53–65
62. Kety SS, Schmidt CF (1948) The nitrous oxide method for the
quantitative determination of cerebral blood flow in man: theory,
procedure and normal values. J Clin Invest 27(4):476–483.
doi:10.1172/JCI101994
63. Lassen NA (1985) Normal average value of cerebral blood flow
in younger adults is 50 ml/100 g/min. J Cereb Blood Flow
Metab 5(3):347–349. doi:10.1038/jcbfm.1985.48
64. Madsen PL, Holm S, Herning M, Lassen NA (1993) Average
blood flow and oxygen uptake in the human brain during resting
wakefulness: a critical appraisal of the Kety–Schmidt technique.
J Cereb Blood Flow Metab 13(4):646–655. doi:10.1038/jcbfm.
1993.83
65. Boyle PJ, Nagy RJ, O’Connor AM, Kempers SF, Yeo RA, Qualls
C (1994) Adaptation in brain glucose uptake following recurrent
hypoglycemia. Proc Natl Acad Sci USA 91(20):9352–9356
66. Boyle PJ, Kempers SF, O’Connor AM, Nagy RJ (1995) Brain
glucose uptake and unawareness of hypoglycemia in patients
with insulin-dependent diabetes mellitus. N Engl J Med
333(26):1726–1731. doi:10.1056/NEJM199512283332602
67. Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA,
Newman EA (2010) Glial and neuronal control of brain blood
flow. Nature 468(7321):232–243. doi:10.1038/nature09613
68. Zimmer L, Luxen A (2012) PET radiotracers for molecular
imaging in the brain: past, present and future. Neuroimage
61(2):363–370. doi:10.1016/j.neuroimage.2011.12.037
69. Herscovitch P, Markham J, Raichle ME (1983) Brain blood flow
measured with intravenous H2(15)O. I. Theory and error anal-
ysis. J Nucl Med 24(9):782–789
70. Baron JC, Jones T (2012) Oxygen metabolism, oxygen extrac-
tion and positron emission tomography: historical perspective
and impact on basic and clinical neuroscience. Neuroimage
61(2):492–504. doi:10.1016/j.neuroimage.2011.12.036
71. Teves D, Videen TO, Cryer PE, Powers WJ (2004) Activation of
human medial prefrontal cortex during autonomic responses to
hypoglycemia. Proc Natl Acad Sci USA 101(16):6217–6221.
doi:10.1073/pnas.0307048101
72. Bingham EM, Dunn JT, Smith D, Sutcliffe-Goulden J, Reed LJ,
Marsden PK, Amiel SA (2005) Differential changes in brain
glucose metabolism during hypoglycaemia accompany loss of
hypoglycaemia awareness in men with type 1 diabetes mellitus.
An [11C]-3-O-methyl-D-glucose PET study. Diabetologia
48(10):2080–2089. doi:10.1007/s00125-005-1900-6
718 H. M. M. Rooijackers et al.
123
73. Dunn JT, Cranston I, Marsden PK, Amiel SA, Reed LJ (2007)
Attenuation of amydgala and frontal cortical responses to low
blood glucose concentration in asymptomatic hypoglycemia in
type 1 diabetes: a new player in hypoglycemia unawareness?
Diabetes 56(11):2766–2773. doi:10.2337/db07-0666
74. Teh MM, Dunn JT, Choudhary P, Samarasinghe Y, Macdonald
I, O’Doherty M, Marsden P, Reed LJ, Amiel SA (2010) Evo-
lution and resolution of human brain perfusion responses to the
stress of induced hypoglycemia. Neuroimage 53(2):584–592.
doi:10.1016/j.neuroimage.2010.06.033
75. Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T,
Casella V, Fowler J, Hoffman E, Alavi A, Som P, Sokoloff L
(1979) The [18F]fluorodeoxyglucose method for the measure-
ment of local cerebral glucose utilization in man. Circ Res
44(1):127–137
76. Reivich M, Alavi A, Wolf A, Fowler J, Russell J, Arnett C,
MacGregor RR, Shiue CY, Atkins H, Anand A et al (1985)
Glucose metabolic rate kinetic model parameter determination
in humans: the lumped constants and rate constants for
[18F]fluorodeoxyglucose and [11C]deoxyglucose. J Cereb
Blood Flow Metab 5(2):179–192. doi:10.1038/jcbfm.1985.24
77. Holden JE, Mori K, Dienel GA, Cruz NF, Nelson T, Sokoloff L
(1991) Modeling the dependence of hexose distribution volumes
in brain on plasma glucose concentration: implications for
estimation of the local 2-deoxyglucose lumped constant. J Cereb
Blood Flow Metab 11(2):171–182. doi:10.1038/jcbfm.1991.50
78. Suda S, Shinohara M, Miyaoka M, Lucignani G, Kennedy C,
Sokoloff L (1990) The lumped constant of the deoxyglucose
method in hypoglycemia: effects of moderate hypoglycemia on
local cerebral glucose utilization in the rat. J Cereb Blood Flow
Metab 10(4):499–509. doi:10.1038/jcbfm.1990.92
79. Nakanishi H, Cruz NF, Adachi K, Sokoloff L, Dienel GA (1996)
Influence of glucose supply and demand on determination of
brain glucose content with labeled methylglucose. J Cereb
Blood Flow Metab 16(3):439–449. doi:10.1097/00004647-
199605000-00010
80. Spring-Robinson C, Chandramouli V, Schumann WC, Faul-
haber PF, Wang Y, Wu C, Ismail-Beigi F, Muzic RF Jr (2009)
Uptake of 18F-labeled 6-fluoro-6-deoxy-D-glucose by skeletal
muscle is responsive to insulin stimulation. J Nucl Med
50(6):912–919. doi:10.2967/jnumed.109.062687
81. Detre JA, Wang J (2002) Technical aspects and utility of fMRI
using BOLD and ASL. Clin Neurophysiol 113(5):621–634
82. McKenna MC, Dienel GA, Sonnewald U, Waagepetersen HS,
Schousboe A (2012) Energy metabolism of the brain. In: Wayne
Albers R, Siegel GJ (eds) Basic neurochemistry, principles of
molecular, cellular, and medical neurobiology, 8th edn. Elsevier,
Amsterdam
83. Bolo NR, Musen G, Jacobson AM, Weinger K, McCartney RL,
Flores V, Renshaw PF, Simonson DC (2011) Brain activation
during working memory is altered in patients with type 1 dia-
betes during hypoglycemia. Diabetes 60(12):3256–3264. doi:10.
2337/db11-0506
84. Rosenthal JM, Amiel SA, Yaguez L, Bullmore E, Hopkins D,
Evans M, Pernet A, Reid H, Giampietro V, Andrew CM,
Suckling J, Simmons A, Williams SC (2001) The effect of acute
hypoglycemia on brain function and activation: a functional
magnetic resonance imaging study. Diabetes 50(7):1618–1626
85. Anderson AW, Heptulla RA, Driesen N, Flanagan D, Goldberg
PA, Jones TW, Rife F, Sarofin H, Tamborlane W, Sherwin R,
Gore JC (2006) Effects of hypoglycemia on human brain acti-
vation measured with fMRI. Magn Reson Imaging
24(6):693–697. doi:10.1016/j.mri.2006.03.013
86. Detre JA, Wang J, Wang Z, Rao H (2009) Arterial spin-labeled
perfusion MRI in basic and clinical neuroscience. Curr Opin
Neurol 22(4):348–355. doi:10.1097/WCO.0b013e32832d9505
87. Alsop DC, Detre JA, Golay X, Gunther M, Hendrikse J, Her-
nandez-Garcia L, Lu H, Macintosh BJ, Parkes LM, Smits M,
van Osch MJ, Wang DJ, Wong EC, Zaharchuk G (2014) Rec-
ommended implementation of arterial spin-labeled perfusion
MRI for clinical applications: a consensus of the ISMRM per-
fusion study group and the European consortium for ASL in
dementia. Magn Reson Med. doi:10.1002/mrm.25197
88. Boscolo Galazzo I, Storti SF, Formaggio E, Pizzini FB, Fiaschi A,
Beltramello A, Bertoldo A, Manganotti P (2014) Investigation of
brain hemodynamic changes induced by active and passive
movements: a combined arterial spin labeling-BOLD fMRI study.
J Magn Reson Imaging 40(4):937–948. doi:10.1002/jmri.24432
89. Di Costanzo A, Trojsi F, Tosetti M, Schirmer T, Lechner SM,
Popolizio T, Scarabino T (2007) Proton MR spectroscopy of the
brain at 3 T: an update. Eur Radiol 17(7):1651–1662. doi:10.
1007/s00330-006-0546-1
90. van der Graaf M (2010) In vivo magnetic resonance spec-
troscopy: basic methodology and clinical applications. Eur
Biophys J 39(4):527–540. doi:10.1007/s00249-009-0517-y
91. de Graaf RA, Mason GF, Patel AB, Behar KL, Rothman DL
(2003) In vivo 1H-[13C]-NMR spectroscopy of cerebral meta-
bolism. NMR Biomed 16(6–7):339–357. doi:10.1002/nbm.847
92. Hertz L, Gibbs ME, Dienel GA (2014) Fluxes of lactate into,
from, and among gap junction-coupled astrocytes and their
interaction with noradrenaline. Front Neurosci 8:261. doi:10.
3389/fnins.2014.00261
93. Henry PG, Criego AB, Kumar A, Seaquist ER (2010) Mea-
surement of cerebral oxidative glucose consumption in patients
with type 1 diabetes mellitus and hypoglycemia unawareness
using (13)C nuclear magnetic resonance spectroscopy. Meta-
bolism 59(1):100–106. doi:10.1016/j.metabol.2009.07.012
94. van de Ven KC, de Galan BE, van der Graaf M, Shestov AA,
Henry PG, Tack CJ, Heerschap A (2011) Effect of acute
hypoglycemia on human cerebral glucose metabolism measured
by (1)(3)C magnetic resonance spectroscopy. Diabetes
60(5):1467–1473. doi:10.2337/db10-1592
95. Lebon V, Petersen KF, Cline GW, Shen J, Mason GF, Dufour S,
Behar KL, Shulman GI, Rothman DL (2002) Astroglial contri-
bution to brain energy metabolism in humans revealed by 13C
nuclear magnetic resonance spectroscopy: elucidation of the
dominant pathway for neurotransmitter glutamate repletion and
measurement of astrocytic oxidative metabolism. J Neurosci
22(5):1523–1531
96. Gulanski BI, De Feyter HM, Page KA, Belfort-DeAguiar R,
Mason GF, Rothman DL, Sherwin RS (2013) Increased brain
transport and metabolism of acetate in hypoglycemia unaware-
ness. J Clin Endocrinol Metab 98(9):3811–3820. doi:10.1210/jc.
2013-1701
97. Mason GF, Petersen KF, Lebon V, Rothman DL, Shulman GI
(2006) Increased brain monocarboxylic acid transport and uti-
lization in type 1 diabetes. Diabetes 55(4):929–934
98. de Graaf RA (2007) In vivo NMR spectroscopy: principles and
techniques, 2nd edn. Wiley, West Sussex
99. Bischof MG, Mlynarik V, Brehm A, Bernroider E, Krssak M,
Bauer E, Madl C, Bayerle-Eder M, Waldhausl W, Roden M
(2004) Brain energy metabolism during hypoglycaemia in
healthy and type 1 diabetic subjects. Diabetologia
47(4):648–651. doi:10.1007/s00125-004-1362-2
100. de Graaf RA, Pan JW, Telang F, Lee JH, Brown P, Novotny EJ,
Hetherington HP, Rothman DL (2001) Differentiation of glu-
cose transport in human brain gray and white matter. J Cereb
Blood Flow Metab 21(5):483–492. doi:10.1097/00004647-
200105000-00002
101. Gruetter R, Ugurbil K, Seaquist ER (1998) Steady-state cerebral
glucose concentrations and transport in the human brain.
J Neurochem 70(1):397–408
Brain glucose metabolism during hypoglycemia in type 1 diabetes: insights from… 719
123
102. Choi IY, Lee SP, Kim SG, Gruetter R (2001) In vivo mea-
surements of brain glucose transport using the reversible
Michaelis–Menten model and simultaneous measurements of
cerebral blood flow changes during hypoglycemia. J Cereb
Blood Flow Metab 21(6):653–663. doi:10.1097/00004647-
200106000-00003
103. Seaquist ER, Damberg GS, Tkac I, Gruetter R (2001) The effect
of insulin on in vivo cerebral glucose concentrations and rates of
glucose transport/metabolism in humans. Diabetes
50(10):2203–2209
104. van de Ven KC, van der Graaf M, Tack CJ, Heerschap A, de
Galan BE (2012) Steady-state brain glucose concentrations
during hypoglycemia in healthy humans and patients with type 1
diabetes. Diabetes 61(8):1974–1977. doi:10.2337/db11-1778
105. Lee DH, Chung MY, Lee JU, Kang DG, Paek YW (2000)
Changes of glucose transporters in the cerebral adaptation to
hypoglycemia. Diabetes Res Clin Pract 47(1):15–23
106. Uehara Y, Nipper V, McCall AL (1997) Chronic insulin hypo-
glycemia induces GLUT-3 protein in rat brain neurons. Am J
Physiol 272(4 Pt 1):E716–E719
107. Simpson IA, Appel NM, Hokari M, Oki J, Holman GD, Maher
F, Koehler-Stec EM, Vannucci SJ, Smith QR (1999) Blood–
brain barrier glucose transporter: effects of hypo- and hyper-
glycemia revisited. J Neurochem 72(1):238–247
108. Kumagai AK, Kang YS, Boado RJ, Pardridge WM (1995)
Upregulation of blood–brain barrier GLUT1 glucose transporter
protein and mRNA in experimental chronic hypoglycemia.
Diabetes 44(12):1399–1404
109. Alf MF, Duarte JM, Schibli R, Gruetter R, Kramer SD (2013)
Brain glucose transport and phosphorylation under acute insulin-
induced hypoglycemia in mice: an 18F-FDG PET study. J Nucl
Med 54(12):2153–2160. doi:10.2967/jnumed.113.122812
110. Criego AB, Tkac I, Kumar A, Thomas W, Gruetter R, Seaquist
ER (2005) Brain glucose concentrations in patients with type 1
diabetes and hypoglycemia unawareness. J Neurosci Res
79(1–2):42–47. doi:10.1002/jnr.20296
111. Criego AB, Tkac I, Kumar A, Thomas W, Gruetter R, Seaquist
ER (2005) Brain glucose concentrations in healthy humans
subjected to recurrent hypoglycemia. J Neurosci Res
82(4):525–530. doi:10.1002/jnr.20654
112. Segel SA, Fanelli CG, Dence CS, Markham J, Videen TO, Para-
more DS, Powers WJ, Cryer PE (2001) Blood-to-brain glucose
transport, cerebral glucose metabolism, and cerebral blood flow are
not increased after hypoglycemia. Diabetes 50(8):1911–1917
113. Bouteldja N, Andersen LT, Moller N, Gormsen LC (2014)
Using positron emission tomography to study human ketone
body metabolism: a review. Metabolism 63(11):1375–1384.
doi:10.1016/j.metabol.2014.08.001
114. Mitchell GA, Kassovska-Bratinova S, Boukaftane Y, Robert
MF, Wang SP, Ashmarina L, Lambert M, Lapierre P, Potier E
(1995) Medical aspects of ketone body metabolism. Clin Invest
Med 18(3):193–216
115. Klepper J, Diefenbach S, Kohlschutter A, Voit T (2004) Effects
of the ketogenic diet in the glucose transporter 1 deficiency
syndrome. Prostaglandins Leukot Essent Fatty Acids
70(3):321–327. doi:10.1016/j.plefa.2003.07.004
116. Beylot M (1996) Regulation of in vivo ketogenesis: role of free
fatty acids and control by epinephrine, thyroid hormones, insulin
and glucagon. Diabetes Metab 22(5):299–304
117. Abi-Saab WM, Maggs DG, Jones T, Jacob R, Srihari V,
Thompson J, Kerr D, Leone P, Krystal JH, Spencer DD, During
MJ, Sherwin RS (2002) Striking differences in glucose and
lactate levels between brain extracellular fluid and plasma in
conscious human subjects: effects of hyperglycemia and hypo-
glycemia. J Cereb Blood Flow Metab 22(3):271–279. doi:10.
1097/00004647-200203000-00004
118. Cooperberg BA, Cryer PE (2010) Insulin reciprocally regulates
glucagon secretion in humans. Diabetes 59(11):2936–2940.
doi:10.2337/db10-0728
119. Boumezbeur F, Petersen KF, Cline GW, Mason GF, Behar KL,
Shulman GI, Rothman DL (2010) The contribution of blood
lactate to brain energy metabolism in humans measured by
dynamic 13C nuclear magnetic resonance spectroscopy. J Neu-
rosci 30(42):13983–13991. doi:10.1523/JNEUROSCI.2040-10.
2010
120. van Hall G, Stromstad M, Rasmussen P, Jans O, Zaar M, Gam
C, Quistorff B, Secher NH, Nielsen HB (2009) Blood lactate is
an important energy source for the human brain. J Cereb Blood
Flow Metab 29(6):1121–1129. doi:10.1038/jcbfm.2009.35
121. Patil GD, Briski KP (2005) Lactate is a critical ‘‘sensed’’ vari-
able in caudal hindbrain monitoring of CNS metabolic stasis.
Am J Physiol Regul Integr Comp Physiol 289(6):R1777–R1786.
doi:10.1152/ajpregu.00177.2004
122. Pellerin L, Magistretti PJ (1994) Glutamate uptake into astro-
cytes stimulates aerobic glycolysis: a mechanism coupling
neuronal activity to glucose utilization. Proc Natl Acad Sci USA
91(22):10625–10629
123. Brooks GA (2009) Cell–cell and intracellular lactate shuttles.
J Physiol 587(Pt 23):5591–5600. doi:10.1113/jphysiol.2009.
178350
124. Jolivet R, Allaman I, Pellerin L, Magistretti PJ, Weber B (2010)
Comment on recent modeling studies of astrocyte-neuron
metabolic interactions. J Cereb Blood Flow Metab
30(12):1982–1986. doi:10.1038/jcbfm.2010.132
125. Mangia S, DiNuzzo M, Giove F, Carruthers A, Simpson IA,
Vannucci SJ (2011) Response to ‘comment on recent modeling
studies of astrocyte-neuron metabolic interactions’: much ado
about nothing. J Cereb Blood Flow Metab 31(6):1346–1353.
doi:10.1038/jcbfm.2011.29
126. Lundgaard I, Li B, Xie L, Kang H, Sanggaard S, Haswell JD,
Sun W, Goldman S, Blekot S, Nielsen M, Takano T, Deane R,
Nedergaard M (2015) Direct neuronal glucose uptake heralds
activity-dependent increases in cerebral metabolism. Nat Com-
mun 6:6807. doi:10.1038/ncomms7807
127. Duarte JM, Girault FM, Gruetter R (2015) Brain energy meta-
bolism measured by (13) C magnetic resonance spectroscopy
in vivo upon infusion of [3-(13) C]lactate. J Neurosci Res
93(7):1009–1018. doi:10.1002/jnr.23531
128. Aveseh M, Nikooie R, Sheibani V, Mahani SE (2014) Endur-
ance training increases brain lactate uptake during
hypoglycemia by up regulation of brain lactate transporters. Mol
Cell Endocrinol. doi:10.1016/j.mce.2014.06.019
129. Herzog RI, Jiang L, Herman P, Zhao C, Sanganahalli BG,
Mason GF, Hyder F, Rothman DL, Sherwin RS, Behar KL
(2013) Lactate preserves neuronal metabolism and function
following antecedent recurrent hypoglycemia. J Clin Invest
123(5):1988–1998. doi:10.1172/JCI65105
130. De Feyter HM, Mason GF, Shulman GI, Rothman DL, Petersen
KF (2013) Increased brain lactate concentrations without
increased lactate oxidation during hypoglycemia in type 1 dia-
betic individuals. Diabetes 62(9):3075–3080. doi:10.2337/db13-
0313
131. Rossetti P, Porcellati F, Busciantella Ricci N, Candeloro P, Cioli
P, Nair KS, Santeusanio F, Bolli GB, Fanelli CG (2008) Effect
of oral amino acids on counterregulatory responses and cogni-
tive function during insulin-induced hypoglycemia in
nondiabetic and type 1 diabetic people. Diabetes
57(7):1905–1917. doi:10.2337/db08-0276
132. Evans ML, Hopkins D, Macdonald IA, Amiel SA (2004) Ala-
nine infusion during hypoglycaemia partly supports cognitive
performance in healthy human subjects. Diabet Med
21(5):440–446. doi:10.1111/j.1464-5491.2004.01174.x
720 H. M. M. Rooijackers et al.
123
133. Schmoll D, Fuhrmann E, Gebhardt R, Hamprecht B (1995)
Significant amounts of glycogen are synthesized from 3-carbon
compounds in astroglial primary cultures from mice with par-
ticipation of the mitochondrial phosphoenolpyruvate
carboxykinase isoenzyme. Eur J Biochem 227(1–2):308–315
134. Wong KL, Tyce GM (1983) Glucose and amino acid metabo-
lism in rat brain during sustained hypoglycemia. Neurochem
Res 8(4):401–415
135. Wahren J, Ekberg K, Fernqvist-Forbes E, Nair S (1999) Brain
substrate utilisation during acute hypoglycaemia. Diabetologia
42(7):812–818
136. Lubow JM, Pinon IG, Avogaro A, Cobelli C, Treeson DM,
Mandeville KA, Toffolo G, Boyle PJ (2006) Brain oxygen uti-
lization is unchanged by hypoglycemia in normal humans:
lactate, alanine, and leucine uptake are not sufficient to offset
energy deficit. Am J Physiol Endocrinol Metab 290(1):E149–
E153. doi:10.1152/ajpendo.00049.2005
137. Ebert D, Haller RG, Walton ME (2003) Energy contribution of
octanoate to intact rat brain metabolism measured by 13C
nuclear magnetic resonance spectroscopy. J Neurosci
23(13):5928–5935
138. Evans ML, Matyka K, Lomas J, Pernet A, Cranston IC, Mac-
donald I, Amiel SA (1998) Reduced counterregulation during
hypoglycemia with raised circulating nonglucose lipid sub-
strates: evidence for regional differences in metabolic capacity
in the human brain? J Clin Endocrinol Metab 83(8):2952–2959.
doi:10.1210/jcem.83.8.4937
139. Page KA, Williamson A, Yu N, McNay EC, Dzuira J,
McCrimmon RJ, Sherwin RS (2009) Medium-chain fatty acids
improve cognitive function in intensively treated type 1 diabetic
patients and support in vitro synaptic transmission during acute
hypoglycemia. Diabetes 58(5):1237–1244. doi:10.2337/db08-
1557
140. Cheah YS, Amiel SA (2012) Metabolic neuroimaging of the
brain in diabetes mellitus and hypoglycaemia. Nat Rev Endo-
crinol 8(10):588–597. doi:10.1038/nrendo.2012.97
141. Cranston I, Reed LJ, Marsden PK, Amiel SA (2001) Changes in
regional brain (18)F-fluorodeoxyglucose uptake at hypo-
glycemia in type 1 diabetic men associated with hypoglycemia
unawareness and counter-regulatory failure. Diabetes
50(10):2329–2336
142. Klomp DW, Renema WK, van der Graaf M, de Galan BE,
Kentgens AP, Heerschap A (2006) Sensitivity-enhanced 13C
MR spectroscopy of the human brain at 3 Tesla. Magn Reson
Med 55(2):271–278. doi:10.1002/mrm.20745
143. van de Ven KC, van der Graaf M, Tack CJ, Klomp DW,
Heerschap A, de Galan BE (2010) Optimized [1-(13)C]glucose
infusion protocol for 13C magnetic resonance spectroscopy at
3T of human brain glucose metabolism under euglycemic and
hypoglycemic conditions. J Neurosci Methods 186(1):68–71.
doi:10.1016/j.jneumeth.2009.10.025
144. van de Ven KC, Tack CJ, Heerschap A, van der Graaf M, de
Galan BE (2013) Patients with type 1 diabetes exhibit altered
cerebral metabolism during hypoglycemia. J Clin Invest
123(2):623–629. doi:10.1172/JCI62742
145. Saez I, Duran J, Sinadinos C, Beltran A, Yanes O, Tevy MF,
Martinez-Pons C, Milan M, Guinovart JJ (2014) Neurons have
an active glycogen metabolism that contributes to tolerance to
hypoxia. J Cereb Blood Flow Metab 34(6):945–955. doi:10.
1038/jcbfm.2014.33
146. Choi IY, Seaquist ER, Gruetter R (2003) Effect of hypoglycemia
on brain glycogen metabolism in vivo. J Neurosci Res
72(1):25–32. doi:10.1002/jnr.10574
147. Oz G, Kumar A, Rao JP, Kodl CT, Chow L, Eberly LE, Seaquist
ER (2009) Human brain glycogen metabolism during and after
hypoglycemia. Diabetes 58(9):1978–1985. doi:10.2337/db09-
0226
148. Herzog RI, Chan O, Yu S, Dziura J, McNay EC, Sherwin RS
(2008) Effect of acute and recurrent hypoglycemia on changes
in brain glycogen concentration. Endocrinology
149(4):1499–1504. doi:10.1210/en.2007-1252
149. Oz G, Tesfaye N, Kumar A, Deelchand DK, Eberly LE, Seaquist
ER (2012) Brain glycogen content and metabolism in subjects
with type 1 diabetes and hypoglycemia unawareness. J Cereb
Blood Flow Metab 32(2):256–263. doi:10.1038/jcbfm.2011.138
150. McKenna MC (2007) The glutamate-glutamine cycle is not
stoichiometric: fates of glutamate in brain. J Neurosci Res
85(15):3347–3358. doi:10.1002/jnr.21444
151. Sonnewald U (2014) Glutamate synthesis has to be matched by
its degradation—where do all the carbons go? J Neurochem
131(4):399–406. doi:10.1111/jnc.12812
152. Dienel GA, McKenna MC (2014) A dogma-breaking concept:
glutamate oxidation in astrocytes is the source of lactate during
aerobic glycolysis in resting subjects. J Neurochem. doi:10.
1111/jnc.12835
153. Garcia-Espinosa MA, Rodrigues TB, Sierra A, Benito M, Fon-
seca C, Gray HL, Bartnik BL, Garcia-Martin ML, Ballesteros P,
Cerdan S (2004) Cerebral glucose metabolism and the glutamine
cycle as detected by in vivo and in vitro 13C NMR spec-
troscopy. Neurochem Int 45(2–3):297–303. doi:10.1016/j.
neuint.2003.08.014
154. Bischof MG, Brehm A, Bernroider E, Krssak M, Mlynarik V,
Krebs M, Roden M (2006) Cerebral glutamate metabolism
during hypoglycaemia in healthy and type 1 diabetic humans.
Eur J Clin Invest 36(3):164–169. doi:10.1111/j.1365-2362.2006.
01615.x
155. Terpstra M, Moheet A, Kumar A, Eberly LE, Seaquist E, Oz G
(2014) Changes in human brain glutamate concentration during
hypoglycemia: insights into cerebral adaptations in hypo-
glycemia-associated autonomic failure in type 1 diabetes.
J Cereb Blood Flow Metab 34(5):876–882. doi:10.1038/jcbfm.
2014.32
156. Jiang L, Herzog RI, Mason GF, de Graaf RA, Rothman DL,
Sherwin RS, Behar KL (2009) Recurrent antecedent hypo-
glycemia alters neuronal oxidative metabolism in vivo. Diabetes
58(6):1266–1274. doi:10.2337/db08-1664
157. Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J (1994)
Effect of hyperketonemia and hyperlacticacidemia on symp-
toms, cognitive dysfunction, and counterregulatory hormone
responses during hypoglycemia in normal humans. Diabetes
43(11):1311–1317
158. King P, Parkin H, Macdonald IA, Barber C, Tattersall RB
(1997) The effect of intravenous lactate on cerebral function
during hypoglycaemia. Diabet Med 14(1):19–28. doi:10.1002/
(SICI)1096-9136(199701)14:1\19:AID-DIA289[3.0.CO;2-0
159. Maran A, Cranston I, Lomas J, Macdonald I, Amiel SA (1994)
Protection by lactate of cerebral function during hypoglycaemia.
Lancet 343(8888):16–20
160. Maran A, Crepaldi C, Trupiani S, Lucca T, Jori E, Macdonald
IA, Tiengo A, Avogaro A, Del Prato S (2000) Brain function
rescue effect of lactate following hypoglycaemia is not an
adaptation process in both normal and type I diabetic subjects.
Diabetologia 43(6):733–741. doi:10.1007/s001250051371
161. Tallroth G, Ryding E, Agardh CD (1992) Regional cerebral
blood flow in normal man during insulin-induced hypoglycemia
and in the recovery period following glucose infusion. Meta-
bolism 41(7):717–721
162. Eckert B, Ryding E, Agardh CD (1998) Sustained elevation of
cerebral blood flow after hypoglycaemia in normal man. Dia-
betes Res Clin Pract 40(2):91–100
Brain glucose metabolism during hypoglycemia in type 1 diabetes: insights from… 721
123
163. Tallroth G, Ryding E, Agardh CD (1993) The influence of
hypoglycaemia on regional cerebral blood flow and cerebral
volume in type 1 (insulin-dependent) diabetes mellitus. Dia-
betologia 36(6):530–535
164. MacLeod KM, Gold AE, Ebmeier KP, Hepburn DA, Deary IJ,
Goodwin GM, Frier BM (1996) The effects of acute hypo-
glycemia on relative cerebral blood flow distribution in patients
with type I (insulin-dependent) diabetes and impaired hypo-
glycemia awareness. Metabolism 45(8):974–980
165. MacLeod KM, Hepburn DA, Deary IJ, Goodwin GM, Dougall
N, Ebmeier KP, Frier BM (1994) Regional cerebral blood flow
in IDDM patients: effects of diabetes and of recurrent severe
hypoglycaemia. Diabetologia 37(3):257–263
166. Arbelaez AM, Su Y, Thomas JB, Hauch AC, Hershey T, Ances
BM (2013) Comparison of regional cerebral blood flow
responses to hypoglycemia using pulsed arterial spin labeling
and positron emission tomography. PLoS One 8(3):e60085.
doi:10.1371/journal.pone.0060085
167. Mangia S, Tesfaye N, De Martino F, Kumar AF, Kollasch P,
Moheet AA, Eberly LE, Seaquist ER (2012) Hypoglycemia-
induced increases in thalamic cerebral blood flow are blunted in
subjects with type 1 diabetes and hypoglycemia unawareness.
J Cereb Blood Flow Metab 32(11):2084–2090. doi:10.1038/
jcbfm.2012.117
168. Musen G, Simonson DC, Bolo NR, Driscoll A, Weinger K, Raji
A, Theberge J, Renshaw PF, Jacobson AM (2008) Regional
brain activation during hypoglycemia in type 1 diabetes. J Clin
Endocrinol Metab 93(4):1450–1457. doi:10.1210/jc.2007-2007
169. Page KA, Arora J, Qiu M, Relwani R, Constable RT, Sherwin
RS (2009) Small decrements in systemic glucose provoke
increases in hypothalamic blood flow prior to the release of
counterregulatory hormones. Diabetes 58(2):448–452. doi:10.
2337/db08-1224
170. Arbelaez AM, Powers WJ, Videen TO, Price JL, Cryer PE
(2008) Attenuation of counterregulatory responses to recurrent
hypoglycemia by active thalamic inhibition: a mechanism for
hypoglycemia-associated autonomic failure. Diabetes
57(2):470–475. doi:10.2337/db07-1329
171. Newman EA (2013) Functional hyperemia and mechanisms of
neurovascular coupling in the retinal vasculature. J Cereb Blood
Flow Metab 33(11):1685–1695. doi:10.1038/jcbfm.2013.145
172. Vetri F, Xu H, Paisansathan C, Pelligrino DA (2012) Impair-
ment of neurovascular coupling in type 1 diabetes mellitus in
rats is linked to PKC modulation of BK(Ca) and Kir channels.
Am J Physiol Heart Circ Physiol 302(6):H1274–H1284. doi:10.
1152/ajpheart.01067.2011
173. Wessels AM, Rombouts SA, Simsek S, Kuijer JP, Kostense PJ,
Barkhof F, Scheltens P, Snoek FJ, Heine RJ (2006) Microvas-
cular disease in type 1 diabetes alters brain activation: a
functional magnetic resonance imaging study. Diabetes
55(2):334–340
174. Larrabee MG (1995) Lactate metabolism and its effects on
glucose metabolism in an excised neural tissue. J Neurochem
64(4):1734–1741
175. Wyss MT, Jolivet R, Buck A, Magistretti PJ, Weber B (2011)
In vivo evidence for lactate as a neuronal energy source.
J Neurosci 31(20):7477–7485. doi:10.1523/JNEUROSCI.0415-
11.2011
176. Litvin M, Clark AL, Fisher SJ (2013) Recurrent hypoglycemia:
boosting the brain’s metabolic flexibility. J Clin Invest
123(5):1922–1924. doi:10.1172/JCI69796
177. Vafaee MS, Vang K, Bergersen LH, Gjedde A (2012) Oxygen
consumption and blood flow coupling in human motor cortex
during intense finger tapping: implication for a role of lactate.
J Cereb Blood Flow Metab 32(10):1859–1868. doi:10.1038/
jcbfm.2012.89
178. Bergersen LH, Gjedde A (2012) Is lactate a volume transmitter
of metabolic states of the brain? Front Neuroenergetics 4:5.
doi:10.3389/fnene.2012.00005
179. Gordon GR, Choi HB, Rungta RL, Ellis-Davies GC, MacVicar
BA (2008) Brain metabolism dictates the polarity of astrocyte
control over arterioles. Nat New Biol 456(7223):745–749.
doi:10.1038/nature07525
180. Lauritzen KH, Morland C, Puchades M, Holm-Hansen S,
Hagelin EM, Lauritzen F, Attramadal H, Storm-Mathisen J,
Gjedde A, Bergersen LH (2013) Lactate receptor sites link
neurotransmission, neurovascular coupling, and brain energy
metabolism. Cereb Cortex. doi:10.1093/cercor/bht136
181. Cryer PE (2008) Hypoglycemia: still the limiting factor in the
glycemic management of diabetes. Endocr Pract 14(6):750–756.
doi:10.4158/EP.14.6.750
722 H. M. M. Rooijackers et al.
123
